ACON Aclarion, Inc.
$2.04▲ +6.25%
Healthcare
Other
Volume 12.5K
Avg Volume (10D) 17.8K
Key Metrics & Fundamentals
Market Cap
$5.88M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.85 - 9.36
% vs 50 MA
-13.41%
% vs 200 MA
-29.08%
RSI-14
43.3
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.98
Free Cash Flow
-$2.70M
Gross Rev
$25,208
Gross Profit
$8,297
EBITDA
-$2.84M
COGS
$16,911
Operating Exp
$2.91M
Operating Income
-$2.90M
EBIT
-$2.90M
Pretax Income
-$2.75M
Net Income
-$2.75M
EPS (Diluted)
-1.12
Price & Volume History
Loading chart…
Recent News
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Zacks · Oct 28, 2026 7:35 AM ET
HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
Zacks · Oct 27, 2026 7:15 AM ET
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
GlobeNewswire · Oct 22, 2026 7:00 AM ET
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
GlobeNewswire · Oct 20, 2026 7:00 AM ET
Aclarion to Present at the 20th Annual LD Micro Main Event
GlobeNewswire · Oct 13, 2026 7:00 AM ET
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
GlobeNewswire · Oct 8, 2026 7:00 AM ET
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
GlobeNewswire · Sep 29, 2026 7:00 AM ET
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
GlobeNewswire · Aug 20, 2026 7:00 AM ET
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
GlobeNewswire · Aug 12, 2026 7:00 AM ET
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 6, 2026 12:00 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ACON's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.